Evaluation of efficacy of new spectroscopic biomarkers for the detection of early-stage pancreatic cancer.
International clinical registry of patients with chronic myeloid leukaemia.
System of informational support for the Cervical Cancer Screening Programme in the Czech Republic.
Clinical registry monitoring cases of bladder cancers treated with cystectomy and consecutive treatment.
Non-interventional, multicentre, retrospective and prospective study of patients with brain tumours, who have been treated in the Czech Republic according to the common clinical practice.
Clinical registry of haemato-oncological patients in which antimycotic therapy has been administered.
Registry of EGFR mutation testing results in patients with non-small-cell lung cancer (NSCLC) in the Czech Republic.
System of informational support for the Colorectal Cancer Screening Programme in the Czech Republic.
System of informational support for the Breast Cancer Screening Programme in the Czech Republic.
Clinical registry of melanoma patients who have been treated with dabrafenib (Tafinlar®), ipilimumab (Yervoy®), nivolumab (Opdivo®), trametinib (Mekinist®), pembrolizumab (Keytruda®) and/or vemurafenib (Zelboraf®).
Multicentric non-interventional prospective study assessing antiemetic guidelines consistency in chemotherapy-induced nausea and vomiting (CINV) prophylaxis and the impact of CINV on the quality of life on cancer patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC).
Clinical registry of pleural mesothelioma patients who have been treated with pemetrexed (Alimta®).
Clinical registry monitoring the epidemiology of gastrointestinal stromal tumours (GIST) as well as therapeutic approaches and treatment results in GIST patients in the Czech Republic and Slovakia.
Clinical registry of non-small cell lung cancer (NSCLC) patients who have been treated with bevacizumab (Avastin®), erlotinib (Tarceva®), gefitinib (Iressa®), pemetrexed (Alimta®), afatinib (Giotrif®) and/or nintedanib (Vargatef®).